Metformin, a medication routinely used by millions of people with type 2 diabetes, may also play an unexpected role in blocking a significant cause of premature birth, according to research findings published July 25.
The early-stage study, based on results from mice bred to be prone to premature birth, was led by a team of scientists at Cincinnati Children’s along with colleagues in France and Japan. Their findings were posted online in JCI: The Journal of Clinical Investigation.
The study is important for two reasons. First, it details a little-understood molecular pathway that can lead to premature birth by disrupting the function of the decidua – a thick membrane that lines the uterus and supports the continued growth of developing fetuses. Second, the researchers demonstrate – in mice — two successful methods for restoring the lining’s function and achieving healthy, full-term births.
“This proof-of-concept study illuminates a potential mechanism behind premature birth,” says Sudhansu K. Dey, PhD, director of the Division of Reproductive Sciences at Cincinnati Children’s and senior author of the new study. “It also demonstrates possible remedies that are already approved for human use.”
New clues in the mystery of premature birth
The study involved analyzing mice bred to lack the p53 gene in the uterus, a condition known to make pregnancies more likely to end in premature birth. The new study adds new detail to why this occurs.
Without the gene, decidual cells show increased activity of a protein complex called mammalian target of rapamycin complex 1 (mTORC1). They also show reduced activity of a signaling protein called AMP-activated protein kinase (AMPK).
Combined, these two changes can lead to premature cellular aging in the decidua, which in turn, can trick the mother’s body into going into labor. The sooner this occurs, the higher the risk of a miscarriage or premature birth.
Digging deeper, the research team learned that another protein, called sestrin 2, plays a critical role in coordinating the relationship between AMPK and mTORC1 signaling. Levels of sestrin 2 also decline in mice missing the p53 gene.
Discovery leads to intriguing potential solution
The team also reported similar – but less effective – results when treating mice with resveratrol, an anti-oxidant and anti-aging dietary supplement made from grape seed extract.
The latest findings continue a line of research that Dey has pursued for several years. In previous studies, Dey and colleagues discovered that rapamycin, an immune suppressing agent, showed promise in mice at preventing premature birth. However, that medication may be risky for use in pregnant women.
Metformin appears to be a potentially safer alternative that works along the same molecular pathway, Dey says.
Premature birth can be caused by many factors. It remains unclear how many premature births are triggered by early decidual aging, but Dey says it could be a significant number.
Advancing these mice-based findings into a treatment available for would-be mothers at risk for premature birth will require extensive work. The process of preparing and conducting human clinical trials to further test the medications could take several years.
Currently, other investigators are studying metformin and resveratrol for their potential to act as anti-aging drugs. However, Dey says his team has not found any human clinical trials investigating the medications for use in preventing premature birth.
Experts working to reduce stubbornly high premature birth rates in Cincinnati and other cities say the new findings merit further investigation – especially to establish the safety of metformin use during pregnancy.
“I think the study has interesting implications. It forms the first step in a potential new intervention that would have to be carefully evaluated in human clinical trials. Metformin has been widely used, but only to a limited extent in pregnancy. Future studies will be needed,” says Louis Muglia, MD, PhD, director of the Center for Prevention of Preterm Birth at Cincinnati Children’s.
- FDA Approves First and Only Lisinopril Oral Solution for Pediatric Patients
- AptaTRACE: Software That Could Facilitate Drug Development
- Teens Who Smoke Daily Are More Likely to Report Health Complaints
- Statement from the Director of FDA’s Center for Biologics Evaluation and Research
- Closure Not Recommended for People with Heart Defect and Stroke